Screening and referral programs for diabetes and cardiovascular disease: Can community pharmacists bridge the care gap?

被引:0
|
作者
Livet, Melanie [1 ,2 ]
Watson, Amber [3 ]
Pathak, Shweta [4 ]
Humphries, Courtney [5 ]
Roller, Jessica [2 ]
Easter, Jon [2 ]
机构
[1] Univ North Carolina Chapel Hill, Frank Porter Graham Child Dev Inst, UNC Eshelman Sch Pharm, Natl Implementat Res Network, Chapel Hill, NC 27599 USA
[2] Univ North Carolina Chapel Hill, UNC Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC 27599 USA
[3] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
[4] Univ North Carolina Chapel Hill, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA
[5] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
来源
EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY | 2025年 / 17卷
关键词
Community pharmacy; Pharmacy practice; Implementation science; Effectiveness-implementation hybrid type II; Diabetes; Cardiovascular; IMPLEMENTATION; SERVICES; OUTCOMES; HEALTH;
D O I
10.1016/j.rcsop.2024.100539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objectives: Heart disease and diabetes are leading causes of death in the U.S., with timely screening, referrals, and education being critical for effective treatment. The Community-based Valued-driven Care Initiative (CVCI) aimed to develop, implement, and evaluate the feasibility of delivering patient-centered care interventions for high priority disease states in community pharmacies. This article focuses specifically on two of the selected interventions, both of which were screening and referral (S&R) programs for the prevention and treatment of cardiovascular disease (CVD) and diabetes (DM) respectively. This exploratory evaluation was designed as an effectiveness-implementation hybrid Type II study. Its objectives were to assess both implementation and preliminary program effectiveness using mixed data. Methods: Fifteen community pharmacies opted to implement one of the two programs over a 12-month period. Implementation feasibility involved examining program adoption rates by sites and patients; acceptability, appropriateness, feasibility, and intent to sustain use survey scores; and pharmacists' interviews. Program effectiveness was based on patient referral rates, physician follow-up communication rates, and perceived outcomes, collected via patient logs, surveys, and interviews. Results: Two of the 15 sites discontinued participation, yielding an 87 % adoption rate. Patient adoption varied based on contact and screening rates, due to differences in patient recruitment, staffing, and workflow. Pharmacist acceptability, compatibility, and feasibility remained high throughout implementation; however, only three pharmacy sites planned on continuing offering the programs. All at-risk patients were appropriately referred based on screening results, with 65 % having their screening results communicated to their primary healthcare providers. The programs were perceived as beneficial, increasing pharmacists' knowledge and motivation, enhancing relationships with patients, and producing an impact on patients" health. Discussion: Results highlight the implementation feasibility and preliminary outcomes of delivering DM and CVD S&R programs in community pharmacies. However, despite these positive results, most pharmacies did not intend to continue the programs, underscoring the continued need for sustainable clinical services models in nontraditional settings. Success with broader implementation will require a paradigm shift in support of community pharmacists as clinical care extenders.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Diabetes and Cardiovascular Disease Interventions by Community Pharmacists: A Systematic Review
    Evans, Charity D.
    Watson, Erin
    Eurich, Dean T.
    Taylor, Jeff G.
    Yakiwchuk, Erin M.
    Shevchuk, Yvonne M.
    Remillard, Alfred
    Blackburn, David
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (05) : 615 - 628
  • [2] The roles of community pharmacists in cardiovascular disease prevention and management
    George, J.
    McNamara, K.
    Stewart, K.
    AUSTRALASIAN MEDICAL JOURNAL, 2011, 4 (05): : 266 - 272
  • [3] Can community pharmacy successfully bridge the gap in care for housebound patients?
    Kayyali, Reem
    Funnell, Gillian
    Harrap, Nicola
    Patel, Anil
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (04) : 425 - 439
  • [4] Understandings, Attitudes, and Barriers About Diabetes Care: Analysis of Factors Influencing Community Pharmacists in China
    Wang, Jia
    Pei, Yuyao
    Yu, Feng
    Kang, Zhen
    Zheng, Yufen
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 1999 - 2009
  • [5] Development of Chronic Kidney Disease Screening Integrative Care Model Led by Community Pharmacists
    Srimongkhol, Piangkwan
    Anutrakulchai, Sirirat
    Theeranut, Amponpun
    Methakanjanasak, Nonglak
    Lertsinudom, Sunee
    PHARMACY, 2025, 13 (01)
  • [6] I believe community pharmacists can contribute in the early screening and referral of patients at risk for metabolic syndrome. Do you?
    Rajanandh, M. G.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (05) : 1291 - 1291
  • [7] Rural health systems' perceptions of referral to community pharmacists during transitions of care
    Paul, Stephanie
    DiDonato, Kristen L.
    Liu, Yifei
    Hartwig, D. Matthew
    May, Justin
    Schramm, Andrew M.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2016, 56 (05) : 562 - +
  • [8] The Effectiveness of Screening for Diabetes and Cardiovascular Disease Risk Factors in a Community Pharmacy Setting
    Willis, Andrew
    Rivers, Peter
    Gray, Laura J.
    Davies, Melanie
    Khunti, Kamlesh
    PLOS ONE, 2014, 9 (04):
  • [9] Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration
    Chang, Lee-Shing
    Vaduganathan, Muthiah
    Plutzky, Jorge
    Aroda, Vanita R.
    CURRENT DIABETES REPORTS, 2019, 19 (12)
  • [10] An explanatory model of community pharmacists' support in the secondary prevention of cardiovascular disease
    Puspitasari, Hanni P.
    Costa, Daniel S. J.
    Aslani, Parisa
    Krass, Ines
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2016, 12 (01) : 104 - 118